A randomized, double-blind, placebo-controlled, clinical trial of a probiotic/prebiotic supplement for the dietary management of age-related bone loss.
A randomized, double-blind, placebo-controlled, clinical trial of a probiotic/prebiotic supplement for the dietary management of age-related bone loss.
批准号:
10733549
负责人:
Shivani Sahni
金额:
$61.15万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-08-01 至 2028-04-30
关键词:
AdultAgeAge-Related Bone LossAgingAmericanBiochemical MarkersBiomechanicsBone DensityClinicalClinical ResearchClinical TrialsColonCompressive StrengthConsumptionControlled Clinical TrialsDataDevelopmentDietDietary FiberDietary InterventionDouble-Blind MethodDrug PrescriptionsDual-Energy X-Ray AbsorptiometryElderlyEnzymesEquilibriumFecesFermentationFiberFoodFood SupplementsFractureGenesGoalsGuidelinesHealth PromotionHomologous GeneHydrolaseInflammationIntakeInterleukinsMaintenanceMeasuresMediatingMetabolismMicrobeMineralsMusOsteitisOsteopeniaOsteoporosisPathway interactionsPeripheralPlacebo ControlPlacebosPlantsPostmenopauseProbioticsProductionPublic HealthRandomizedRecommendationRegulatory T-LymphocyteShotgun SequencingSkeletonTNF geneTestingVertebral columnVitamin K 2VitaminsVolatile Fatty AcidsWeight-Bearing stateWomanX-Ray Computed Tomographyagedbonebone lossbone massbone strengthbone turnovercomparison controlcostdesigndietaryefficacy testingfracture riskfruits and vegetablesgut microbesgut microbiomeimprovedinflammatory markerinsightmedical foodmetagenomemetatranscriptomemicrobialmiddle agemouse modelnovelolder womenosteoclastogenesisprebioticspreclinical studyprimary outcomesecondary outcomeside effectskeletalspine bone structure
中文摘要
摘要/项目摘要
目前推荐的随年龄增长的初级骨量维持策略仅限于消耗
饮食富含维生素和矿物质,并能进行负重活动。如果没有更具体和有效的
保持骨量的方法随着年龄的增长,老年人会患上骨质疏松症和骨折风险增加
需要处方药,有副作用和限制性成本。因此,对安全的需求尚未得到满足。
对骨质流失的代谢过程进行有效的饮食干预。我们的长期目标是
开发安全有效的益生菌/益生菌组合补充剂,用于肉鸡的饮食管理
骨量减少和骨质疏松症背后的代谢过程。这个项目的目标是测试疗效。
在一项临床试验中,骨骼上的益生菌/益生菌组合(“合生元”)旨在提供
对合生体作用的机械论洞察。我们的中心假设是一种从植物中提取的新型药物
食品合生素(“SBD111”)将改善双能X射线骨密度仪(DXA)来源的腰椎骨
骨密度(BMD)、定量计算机断层扫描(QCT)得出的骨强度(又名生物力学)
计算机断层扫描分析,或BCT-和体积骨密度(VBMD),骨转换的标志,
与安慰剂相比,老年女性(>;60岁)的炎症和肠道微生物群功能。以Strong为指导
初步数据将通过进行为期18个月的随机、双盲、安慰剂试验来检验这一假设。
220例老年妇女的临床对照试验。我们的具体目标是:目标1a和1b,以确定18
每日摄入SBD111几个月对腰椎DXA-BMD和二次结局的影响
(BCT得出的椎体压缩骨强度、vBMD和骨转换标志物)。目标2a
和2b确定每天摄入SBD111 18个月对炎症和肠道标志物的影响
微生物群在女性中的作用。我们将使用整个元基因组和元转录组鸟枪式测序
解剖肠道微生物组功能的变化[定义为糖基水解酶、孟喹酮7、
链脂肪酸(SCFA)和微生物多样性],这可以介导SBD111对骨转换和
发炎。我们还将考虑摄入总膳食纤维、益生菌纤维和益生菌食物,这些食物可能
修改SBD111对骨骼、炎症和肠道微生物群的影响。
如果成功,这项拟议的试验将导致开发潜在的安全、廉价的健康促进策略
用于骨量减少和骨质疏松症的代谢过程的饮食管理。
1
英文摘要
ABSTRACT / PROJECT SUMMARY
Currently recommended strategies for primary maintenance of bone mass with age are limited to consuming a
diet rich in vitamins and minerals and performing weight bearing activity. Without more specific and effective
ways to maintain bone mass with age, older adults will develop osteoporosis and elevated fracture risk
necessitating prescription drugs, with side effects and restrictive costs. Hence, there is an unmet need for safe
and effective dietary interventions for the metabolic processes underlying bone loss. Our long term goal is to
develop safe and effective prebiotic/probiotic combination supplements for the dietary management of the
metabolic processes underlying osteopenia and osteoporosis. The objective of this project is to test the efficacy
of an probiotic/prebiotic combination (“synbiotic”) on the skeleton in a clinical trial that is designed to provide
mechanistic insights into the action of the synbiotic. Our central hypothesis is that a novel plant-derived medical
food synbiotic (“SBD111”) will improve dual energy x-ray absorptiometry (DXA) derived lumbar spine bone
mineral density (BMD), quantitative computed tomography (QCT) derived bone strength — aka Biomechanical
Computed Tomography analysis, or BCT— and volumetric BMD (vBMD), markers of bone turnover,
inflammation, and gut microbiome function in older women (>60 years) compared to placebo. Guided by strong
preliminary data this hypothesis will be tested by performing an 18-month randomized, double-blinded, placebo-
controlled clinical trial in 220 older women. Our specific aims are: Aim 1a and 1b To determine the effect of 18
months of daily intake of SBD111 on the primary outcome of lumbar spine DXA-BMD and secondary outcomes
(BCT-derived vertebral compressive bone strength, vBMD, and markers of bone turnover) in women. Aim 2a
and 2b To determine the effect of 18 months of daily intake of SBD111 on markers of inflammation and gut
microbiome function in women. We will employ whole metagenome and meta-transcriptome shotgun sequencing
to dissect changes in gut microbiome function [defined as changes in glycosyl hydrolase, menaquinone 7, short
chain fatty acid (SCFA), and microbial diversity], which can mediate the effect of SBD111 on bone turnover and
inflammation. We will also consider intake of total dietary fiber, prebiotic fiber, and probiotic foods that could
modify the effect of SBD111 on bone, inflammation, and gut microbiome.
If successful, this proposed trial will lead to developing potentially safe, inexpensive health promoting strategies
for the dietary management of the metabolic processes underlying osteopenia and osteoporosis.
1
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel Factors for Muscle Mass and Strength in Adults
-
批准号:9324114
-
项目类别:
-
资助金额:$38.55万
-
财政年份:2016
-
负责人:Shivani Sahni
-
依托单位:
Novel Factors for Muscle Mass and Strength in Adults
-
批准号:9175681
-
项目类别:
-
资助金额:$35.75万
-
财政年份:2016
-
负责人:Shivani Sahni
-
依托单位:
Uric Acid, Vitamin C and Bone Health: The Framingham Study
-
批准号:8447230
-
项目类别:
-
资助金额:$8.25万
-
财政年份:2013
-
负责人:Shivani Sahni
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: